Articles from Bluejay Diagnostics, Inc.

Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness 

ACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQBJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced financial results for the quarter and six months ended June 30, 2022.